TNFR2

TNFR2 詳細

英語名Tumor necrosis factor receptor superfamily member 1B市販薬剤の数1
治験薬の数8ターゲットの別称TNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
研究&開発段階Approved
英語名Tumor necrosis factor receptor superfamily member 1B
ターゲットの別称TNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
市販薬剤の数1
治験薬の数8
研究&開発段階Approved

TNFR2バックグランド

TNFR2 (tumor necrosis factor receptor superfamily member 1B) is a receptor with high affinity for TNFSF2/TNF-alpha. It has a much lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. TNFR2 mediates most of the metabolic effects of TNF-alpha.

TNFR2分子の別称

TNFRSF1B,CD120b,TBPII,TNF-R-II,TNF-R75,TNFBR,TNFR1B,TNFR2,TNFR80,p75,p75TNFR

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
LBL-019LBL-019Phase 2 ClinicalNanjing Leadsbiolabs Co LtdNeoplasms
詳細
BI-1910BI-1910Phase 2 ClinicalBioinvent International AbCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours
詳細
BITR-2101BITR-2101; BIR-2101; BITT2101; BITT-2101Phase 1 ClinicalBoston Immune Technologies & TherapeuticsInfections; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms
詳細
TRB-061TRB-061Phase 1 ClinicalTrex Bio IncColitis; Dermatitis; Dermatitis, Atopic
詳細
NBL-020Phase 1 ClinicalShanghai Xinshi Biological Medicine Co LtdNeoplasms; Solid tumours
詳細
BC-011BC-011Phase 1 ClinicalDragonboat BiopharmaceuticalSolid tumours
詳細
SIM1811-03SIM1811-03; SIM0235; SIM-235Phase 1 ClinicalJiangsu Simcere Pharmaceutical Co LtdLymphoma, T-Cell, Cutaneous; Neoplasms; Solid tumours
詳細
EmunkitugHFB-2003; HFB-200301Phase 1 ClinicalHiFiBiO TherapeuticsCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Germinoma; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Testicular Neoplasms; Uterine Cervical Neoplasms
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)ApprovedHisun Biopharmaceutical Co LtdMainland ChinaSpondylitis, Ankylosing; Psoriasis; Arthritis, RheumatoidHisun Biopharmaceutical Co Ltd2015-04-09Arthritis, Rheumatoid; Psoriasis; Spondylitis, Ankylosing
詳細
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8